Cargando…

Management of Diarrhea in Patients With Carcinoid Syndrome

Neuroendocrine tumors (NETs) arise from enterochromaffin cells found in neuroendocrine tissues, with most occurring in the gastrointestinal tract. The global incidence of NETs has increased in the past 15 years, likely due to better diagnostic methods. Small-bowel NETs are frequently associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naraev, Boris G., Halland, Magnus, Halperin, Daniel M., Purvis, Amy J., O'Dorisio, Thomas M., Halfdanarson, Thorvardur R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867674/ https://www.ncbi.nlm.nih.gov/pubmed/31425482 http://dx.doi.org/10.1097/MPA.0000000000001384

Ejemplares similares

Direct costs of carcinoid syndrome diarrhea among adults in the United States
por: Dasari, Arvind, et al.
Publicado: (2019)

Optimizing the Management of Carcinoid Syndrome to Reduce the Impact of Diarrhea
por: Randall, Rory, et al.
Publicado: (2019)

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
por: Gelhorn, Heather L., et al.
Publicado: (2016)

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
por: Dillon, Joseph S., et al.
Publicado: (2020)

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues
por: Anthony, Lowell B., et al.
Publicado: (2021)

SUN-LB26 Radioligand Theranostics of Endocrine-Related Cancers; A New, Revolutionary Approach
por: Harris, Alan G, et al.
Publicado: (2020)

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
por: Saavedra, Cristina, et al.
Publicado: (2019)

Growing vascular endothelial cells express somatostatin subtype 2 receptors
por: Watson, J C, et al.
Publicado: (2001)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome
por: Halperin, Daniel M., et al.
Publicado: (2019)

Gastroenteropancreatic neuroendocrine tumors in children and young adults
por: Khanna, Geetika, et al.
Publicado: (2007)

Prospective Analysis of the Impact of (68)Ga-DOTATOC Positron Emission Tomography–Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors
por: Ghobrial, Silvia N., et al.
Publicado: (2020)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

The Carcinoid Syndrome
Publicado: (1973)

Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea
por: Gregersen, Tine, et al.
Publicado: (2016)

Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study
por: Halperin, Daniel M., et al.
Publicado: (2018)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis
por: Alexandraki, Krystallenia I., et al.
Publicado: (2023)

Advances in systemic therapy for advanced pancreatobiliary malignancies
por: Halfdanarson, Thorvardur R, et al.
Publicado: (2013)

The current status of somatostatin receptors in malignant melanoma.
por: Fletcher, W. S., et al.
Publicado: (1997)

The Carcinoid Syndrome
por: Strahan, Jack
Publicado: (1961)

Mayo Clinic Cancer Center Experience of Metastatic Extramammary Paget Disease 1998-2012
por: Padrnos, Leslie, et al.
Publicado: (2016)

Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
por: Diamantopoulos, Leonidas N., et al.
Publicado: (2023)

Targeted Alpha-Particle Therapy: A Review of Current Trials
por: Jang, Albert, et al.
Publicado: (2023)

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
por: Bushnell, David L, et al.
Publicado: (2014)

Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female
por: Cogen, Jonathan D., et al.
Publicado: (2016)

Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome
por: Shogbesan, Oluwaseun, et al.
Publicado: (2018)

Primary neuroendocrine carcinoma of the brain
por: Reed, Clay T, et al.
Publicado: (2019)

Carcinoid syndrome: update on the pathophysiology and treatment
por: de Celis Ferrari, Anezka C. Rubin, et al.
Publicado: (2018)

Multidisciplinary team management of carcinoid heart disease
por: Steeds, Richard P, et al.
Publicado: (2019)

Developments in the treatment of carcinoid syndrome – impact of telotristat
por: Chan, David L, et al.
Publicado: (2018)

Cases in a series of carcinoid syndrome and carcinoid heart disease
por: Mamotabo, R Matshela
Publicado: (2018)

Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome
por: Clement, Dominique, et al.
Publicado: (2020)

Complications from carcinoid syndrome: review of the current evidence
por: Mota, José Mauricio, et al.
Publicado: (2016)

Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies
por: Vitale, Giovanni, et al.
Publicado: (2023)

The role of serotonin inhibition within the treatment of carcinoid syndrome
por: George, Joel, et al.
Publicado: (2023)

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
por: Abad, Catalina, et al.
Publicado: (2016)

Erratum to: VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
por: Abad, Catalina, et al.
Publicado: (2017)

Pilot Study Characterizing the Hematology-Oncology Fellow Job Search Process: Tools Used and Identification of Potential New Resources
por: Marshall, Ariela L., et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
por: Starr, Jason S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pr11u23607pdrbapma10n4njd6